Circulating Tumor DNA as a Biomarker for Precision Medicine in Prostate Cancer: A Systematic Review
International Journal of Molecular Sciences · 15.11.2025 · 26 (22) · 11049
DOI: 10.3390/ijms262211049 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 15.11.2025. Verfasst von Nouhaila Chanhih und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for Research on Health Sciences (CReSS), International Faculty of Medicine, College of Health Sciences, International University of Rabat, Tec…. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Circulating Tumor DNA, Precision Medicine, Prostatic Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Circulating tumor DNA (ctDNA) profiling offers non-invasive insights for personalized prostate cancer management. This systematic review provides the first comprehensive appraisal of ctDNA assay methods, genomic targets, and their clinical correlations and proposes practical recommendations to guide future standardization and validation. We searched PubMed, ScienceDirect, Scopus, and the Cochrane Library starting December 2024 following PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines. From 229 records, 44 studies (10,631 patients) met the inclusion criteria. Plasma ctDNA analyzed by NGS predominantly profiled TP53 (72.7%), AR (70.4%), BRCA1/2 (61.3%), ATM (50%), RB1 (47.7%), and PTEN (41%). ctDNA positivity and specific key alterations correlated with poorer overall and progression-free survival. BRCA1/2-mutant patients benefited from Olaparib plus Abiraterone, while persistent alterations predicted early progression. Beyond synthesizing existing evidence, we identify key gaps, such as inconsistent reporting of variant allele fractions, limited diversity in study populations, and underexplored rare alterations. We recommend unified reporting standards (e.g., variant allele frequency thresholds and panel composition) and prioritized prospective trials to validate high-impact targets. These steps will accelerate the integration of ctDNA into routine precision oncology practice worldwide.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Research on Health Sciences (CReSS), International Faculty of Medicine, College of Health Sciences, International University of Rabat, Technopolis Parc, Rocade of Rabat-Salé, Sala-Al Jadida 11100, Morocco.
- Laboratory of Virology, Center of Virology, Infectious and Tropical Diseases, Mohammed V Military Teaching Hospital, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat 10045, Morocco.
- Biomedical and Epidemiological Research Unit, Center of Virology, Infectious and Tropical Diseases, Mohammed V Military Teaching Hospital, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat 10045, Morocco.
- Laboratory of Biology and Human Pathologies, Department of Biology, Faculty of Sciences of Rabat, University Mohammed V of Rabat, Rabat 10000, Morocco.
- Department of Urology, Mohammed V Military Teaching Hospital, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat 10045, Morocco.
- Center of Virology, Infectious and Tropical Diseases, Mohammed V Military Teaching Hospital, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat 10045, Morocco.
ORCID-Profile: Abdelilah Laraqui, Salma Hassine, Larbi Hamedoun, Mohamed Rida Tagajdid, Abdelaziz Benjouad
Zitieren
APA
Chanhih, N., Laraqui, A., Hassine, S., Ameur, A., Hamedoun, L., El Annaz, H., Abi, R., Tagajdid, M. R., Amine, I. L., Ennibi, K., Benjouad, A., & Belayachi, L. (2025). Circulating Tumor DNA as a Biomarker for Precision Medicine in Prostate Cancer: A Systematic Review. International Journal of Molecular Sciences, 26(22), 11049. https://doi.org/10.3390/ijms262211049
Vancouver
Chanhih N, Laraqui A, Hassine S, Ameur A, Hamedoun L, El Annaz H, et al. Circulating Tumor DNA as a Biomarker for Precision Medicine in Prostate Cancer: A Systematic Review. International Journal of Molecular Sciences. 2025;26(22):11049. doi:10.3390/ijms262211049
BibTeX
@article{Chanhih2025,
author = {Chanhih, Nouhaila and Laraqui, Abdelilah and Hassine, Salma and Ameur, Ahmed and Hamedoun, Larbi and El Annaz, Hicham and Abi, Rachid and Tagajdid, Mohamed Rida and Amine, Idriss Lahlou and Ennibi, Khalid and Benjouad, Abdelaziz and Belayachi, Lamiae},
title = {Circulating Tumor DNA as a Biomarker for Precision Medicine in Prostate Cancer: A Systematic Review},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {22},
pages = {11049},
doi = {10.3390/ijms262211049}
}
EUVIMED